Alzamend Neuro Business Summary

Alzamend Neuro, Inc. (ALZN) is a clinical-stage biopharmaceutical company primarily focused on the development and future commercialization of patented intellectual properties licensed from the University of South Florida Research Foundation. The company operates as a pre-revenue entity, with its business model centered on advancing two core therapeutic candidates through the clinical trial pipeline to secure eventual licensing agreements, partnerships, or direct market sales. Its primary business segments are categorized by its lead drug candidates: AL001, a patented ionic cocrystal technology delivering a combination of lithium, salicylate, and L-proline for Alzheimer’s, bipolar disorder, and PTSD; and ALZN002, a cell-based therapeutic vaccine designed to restore immunological combat against beta-amyloid. In the competitive landscape, Alzamend contends with major players like Biogen and Eli Lilly, as well as specialized biotech firms such as Anavex Life Sciences (AVXL) and Cassava Sciences. Alzamend distinguishes itself by leveraging the 505(b)(2) regulatory pathway for AL001, aiming to provide the therapeutic benefits of lithium at lower, non-toxic doses compared to traditional lithium carbonate treatments. The company was founded by Milton “Todd” Ault III, a seasoned activist investor and the current Vice Chairman and Chairman Emeritus, who initiated the venture under the Ault Alliance umbrella. The leadership team is headed by CEO Stephan Jackman, who joined in 2018 with over 20 years of experience in the biopharmaceutical sector, including previous roles at Novartis and Ennaid Therapeutics. Supporting the executive suite are CFO David J. Katzoff, who brings three decades of financial expertise in healthcare and technology, and Henry C.W. Nisser, who serves as Executive Vice President and General Counsel. The Board of Directors is chaired by William B. Horne and includes notable members such as Dr. Andrew H. Woo and Dr. Lynne Fahey McGrath, the latter of whom possesses extensive regulatory experience from Novartis and Regenxbio. Significant institutional backing is provided by firms such as Geode Capital Management, Citadel Advisors, and Vanguard, while Milton Ault III remains the largest individual stakeholder through his various investment vehicles.